TerminatedNCT00746421
Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolarity
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Atlanta and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateJanuary 2010
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 32
- Sponsor
- Emory University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00746421
- Official title
Show the full official title
Phase IV Study of Quetiapine XR Aimed at Disability and Cognitive Impairments.
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Atlanta · Durham
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Emory University, a university.
Does this study involve medication?
Yes. The study involves medication, including Quetiapine XR and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.